Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

To learn more, see this website. The price per dose of Ocrevus and cost per infusion depend on several individual factors. These include: whether you have insurance or whether you are paying out ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Until the FDA approval of Ocrevus intravenous (IV) infusion, there had been no FDA-approved treatments for PPMS and Ocrevus IV and Ocrevus Zunovo are the only approved treatments for PPMS.

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

The Swiss pharmaceutical giant said Wednesday that the trial compared a high dose of Ocrevus intravenous infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing multiple ...

Group, announced that the Phase 3 MUSETTE trial comparing a high dose of Ocrevus intravenous infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing multiple sclerosis did ...